IL-6 involvement in epithelial cancers
Open Access
- 3 December 2007
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 117 (12), 3660-3663
- https://doi.org/10.1172/jci34237
Abstract
In this issue of the JCI, two reports provide intriguing new information on the role of the inflammatory cytokine IL-6 in breast and lung cancer. The study by Sansone et al. implicates IL-6 in the instigation of malignant properties in breast cancer stem cells (see the related article beginning on page 3988). The study by Gao et al. identifies mutant variants of EGFR as inducers of IL-6 in lung adenocarcinomas (see the related article beginning on page 3846). These studies add to our understanding of potential roles for IL-6 in cancer and further motivate investigations of IL-6–targeted chemotherapeutics.Keywords
This publication has 22 references indexed in Scilit:
- IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary glandJCI Insight, 2007
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJCI Insight, 2007
- Oncogenic Ras-induced secretion of IL6 is required for tumorigenesisGenes & Development, 2007
- Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancerBreast Cancer Research, 2007
- β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary TumorigenesisCell, 2006
- The role of IL-6 and STAT3 in inflammation and cancerEuropean Journal Of Cancer, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- INTERLEUKIN-6: From Basic Science to Medicine—40 Years in ImmunologyAnnual Review of Immunology, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003